ALL Leukemia

SLIDES & TRANSCRIPTS
Monday, May 12, 2003

Allogeneic and autologous SCT

Stephen J. Forman, M.D.

Slide 1:

We are going to try to get several things done in this session. We actually have four speakers in these 15 minutes for transplants.

As Dr. Schiffer said, he is surprised they gave us that much time to cover all the transplantation, but I think we will do the best that we can.

What I am going to do, I am going to show you an update of some data on the post-remission patients in the adults. Tony and Jacob will review the current status of the ECOG MRC study. Charlie will talk a little bit about autologous transplants, and then I will finish up by showing some early data on a concept utilizing gene-modified T cells for the treatment of ALL.

Just a very brief update on the CPUP Stanford data set for ALL in first remission.

TOP

Slide 2:

These are patients who had high risk factors of either Ph positive disease, 411, longer than six weeks to go into remission, or high white count in the pre-B phenotype.

Slide 3:

Just in the interest of time, this is the current update of that patient group,

Slide 4:

showing about a 65 percent disease free survival, with a median follow up now of six years, and a relapse rate of approximately 15 percent in the first remission group.

Slide 5:

If you look at the second CR group with a similar regimen, the data is not quite as good. It is about a 50 percent disease-free survival for patients who did not have poor risk B as a diagnosis, but who relapsed and went to transplant thereafter.

Slide 6:

If you look at the relapse rate or the comparative relapse rate of the two groups of patients, as you might expect and would predict, the relapse rate is about twice as high in the second remission patients as it is in the first remission patients.

So, it gives you a sense of what can be achieved with the high risk adult and the adult who relapses and goes into second remission with this kind of allogeneic sibling transplant. What I will do is, I will stop there and ask Jacob and Tony to present at least a current update, the most recent update, I should say, of the MRC trial.